News Headlines Article

Amgen wins approval for second biotech cholesterol drug
Baltimore Sun

Amgen Inc. has won federal approval for the second medicine in a new class of pricey biotech drugs that reduce artery-clogging cholesterol more than older statin drugs that have been used for decades.

The drug Repatha could eventually help millions of Americans who face increased risks of heart disease because they cannot control their cholesterol with existing drugs and methods. But concerns about the medication’s price tag — $14,100 per year — and long-term benefits will likely limit its use in the near-term.